Is Remote GMP Auditing in Pharma Viable in the Long Term?

New research conducted in February 2022 assessed how well remote auditing fulfilled clients’ needs. The findings are summarised in this report.

Topic: GMP Auditing, Biopharmaceuticals

Whitepaper cover

About this paper

New research conducted in February 2022 assessed how well remote auditing fulfilled clients’ needs during two years of COVID 19-related disruption, and the longer-term preferences that are emerging as restrictions are lifted.

The findings are summarised in this report.

We simply wouldn’t go anywhere else. Rephine has the credentials and the proven track record.

Alasdair Leckie Headshot

About the author

Alasdair Leckie,
Operations Manager, Rephine

Alasdair Leckie is Operations Manager at Rephine, a firm of deeply experienced GMP auditors which proactively help pharmaceutical companies around the world with their supply-chain quality assurance. Alasdair has been with Rephine for nine years and has a Bachelor’s Degree in Chinese and Economics from SOAS University of London.

Download The Report

Newsletter